The discovery of new cancer therapeutics has led to a significant increase in the number of cancer survivors. More individuals are cured from their cancer today, while there is also a growing number of individuals living with their disease. With the advancements and improved cancer survival, many cancer survivors experience both long-term and short-term cardiovascular effects. These cardiovascular complications have a major impact on mortality and mortality, at times exceeding that of the primary malignancy.

With a decline in cancer mortality, cardiovascular disease has emerged as a competing cause of death. Cancer survivors now demonstrate 2-5 times higher risk of mortality due to cardiovascular disease than the general population, impacting the gains achieved in cancer survival. In response to the growing concerns of the CV challenges faced by patients with cancer, the field of cardio-oncology has evolved, which consists of experts in both cancer and cardiology working to improve the detection, monitoring and treatment of CV disease at each stage of the cancer care continuum. The field is rapidly growing as it advances to meet the urgent need to improve the cardiovascular health of patients with cancer.

Learning Objectives

• Identify common risk factors for the development of cardiac complications in cancer survivors

• Recognize advances in the use of cardiac imaging, biomarkers in cancer patients receiving cardiac toxic medications

• Understand the utilization of cardioprotective strategies for individuals receiving cardiotoxic medications

• Identify common thrombotic and bleeding complications in cancer patients

Target Audience

This symposium is intended for physicians, physician assistants, nurses and nurse practitioners, pharmacists, and researchers who work in cardiology or oncology. It is also intended for primary care providers and medical specialists who are interested in learning more about the ongoing needs of cancer survivors as it relates to cardiology. Students are also welcome.